A team of researchers from England sought to establish whether bone disease is present at diagnosis in inflammatory bowel disease (IBD), and to identify any contributory metabolic abnormalities.
The team compared patients with newly diagnosed IBD against standard reference ranges and a control group with irritable bowel syndrome.
The IBD group had a mean age of 44 years, and was comprised of 19 males and 15 females, 23 patients had ulcerative colitis and 11 Crohn's disease.
The control group of 8 males and 10 females had a mean age of 40 years.
The team measured bone mineral density and biochemical bone markers.
|Femoral neck bone mineral density lower in IBD patients.|
|Alimentary Pharmacology and Therapeutics|
The researchers found that femoral neck bone mineral density, T- and Z-scores were lower in IBD patients than in irritable bowel syndrome control.
Furthermore, lumbar spine bone mineral density and T-scores were also significantly lower in patients than controls.
Compared with controls, the urinary deoxypyridinoline : creatinine ratio was increased and serum 25-hydroxy vitamin D was decreased in the IBD group. Plasma osteocalcin and serum parathyroid hormone did not differ.
Dr Lamb's team concluded, "The bone mineral density is reduced at diagnosis, prior to corticosteroid treatment, in both Crohn's disease and ulcerative colitis".
"Our data suggest that this is attributable to increased resorption rather than decreased bone formation".